McClelland R A, Berger U, Miller L S, Powles T J, Jensen E V, Coombes R C
Cancer Res. 1986 Aug;46(8 Suppl):4241s-4243s.
We have used an immunoperoxidase technique utilizing a monoclonal antibody to the estradiol receptor to identify immunoreactive estradiol receptor in breast carcinomas and have examined the relationship between the immunoreactive estradiol receptor and response to therapy in patients with advanced breast cancer. Fifty-six patients were found to be assessable for response to endocrine therapy. Twenty-two showed an objective response to some form of endocrine manipulation, and all these had positively stained carcinomas. None of the 17 patients with negatively stained carcinomas responded to endocrine therapy. We conclude that the monoclonal antibody to estradiol receptor can help identify breast cancer patients who may respond to endocrine therapy.
我们运用了一种免疫过氧化物酶技术，该技术利用针对雌二醇受体的单克隆抗体来识别乳腺癌中的免疫反应性雌二醇受体，并研究了晚期乳腺癌患者中免疫反应性雌二醇受体与治疗反应之间的关系。发现56例患者可评估内分泌治疗反应。22例对某种形式的内分泌干预呈现客观反应，并且所有这些患者的癌组织染色均为阳性。17例癌组织染色为阴性的患者均未对内分泌治疗产生反应。我们得出结论，针对雌二醇受体的单克隆抗体有助于识别可能对内分泌治疗有反应的乳腺癌患者。
